You are now leaving the ViiV Healthcare website and being re-directed to an external website

  • Healthcare professionals
  • LiV Life PLHIV Site
  • Media
  • Our Stories
  • Careers
  • Countries
    • Australia
    • Canada
    • Netherlands
    • Switzerland
    • France
    • United States
    • Italy
    • Japan
    • Germany
    • Spain
  • Home
  • About us
    • What we do
    • Who we are
    • Where we work
    • Our Stories
  • HIV Treatment and Care
    • Our Medicines
    • Medical Education Events
    • Medicines in development
    • ViiV Exchange website
    • LiV Life PLHIV Site
    • Compassionate Use
  • Advancing Science and R&D
    • We research and develop new HIV medicines
    • We collaborate to innovate
    • We are committed to data transparency
  • Mapping an HIV Free Future
    • Access to Medicines
    • Working towards 90 90 90
    • Policy Papers
    • Paediatric HIV Care
    • Implementation Science
  • Supporting the community
    • New Positive Actions Strategy & Funding
    • Positive Action Legacy Grants
    • Case Studies
  • Open mobile
  • Search

ZIAGEN®

Ziagen (abacavir) is a nucleoside reverse transcriptase inhibitor

Prescribing Information

Please refer to your country-specific information below:

Canada

Product Monograph for Ziagen® /

Monographie de Ziagen

Safety Information / Renseignements sur l’innocuité

Healthcare Professional Letter for Ziagen® / Lettre aux professionnels de la santé sur Ziagen®

Healthcare Professional Letter for Ziagen® / Lettre aux professionnels de la santé sur Ziagen®

Public Advisory on Ziagen® / Avis public sur Ziagen®

Europe

Ziagen tablets summary of Product Characteristics

Ziagen tablets Patient Information Leaflet

Ziagen oral solution summary of Product Characteristics

Ziagen oral solution patient information leaflet

Japan

Information for Healthcare Professionals

United States

Prescribing information and medication guide for Ziagen

Ziagen warning card

Other resources

Safety Data Sheet

Abacavir HSR Support - Information for healthcare professionals and the public on hypersensitivity reactions to abacavir

  • Our Medicines
    • Medicines in development
    • Vocabria
    • Rukobia
    • Cabenuva
    • Dovato®
    • Juluca®
    • Triumeq®
    • Tivicay®
    • Selzentry/Celsentri®
    • Epzicom/Kivexa®
    • Ziagen®
    • Trizivir®
    • Combivir®
    • Epivir/3TC®
    • Retrovir/AZT®
    • Lexiva/Telzir®
    • Viracept®
    • Rescriptor®

Related articles

Report a side effect

viivhelathcare

Connect with us

  • facebook
  • twitter
  • instagram
  • linkedin
  • youtube

Contact us

ViiV Healthcare
980 Great West Road
Brentford
Middlesex
TW8 9GS
UK

Tel. +44 (0)20 8380 6200

View our full list of locations

  • Terms of use
  • Accessibility
  • Cookie policy
  • Privacy notice
  • Modern Slavery Statement
  • Terms and conditions
  • Sitemap

Report an adverse event

To report a suspected side effect, please use our online reporting form.

©2019 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare UK Limited. Registered in England and Wales No. 06990358.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.